[go: up one dir, main page]

AR028579A1 - Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica - Google Patents

Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica

Info

Publication number
AR028579A1
AR028579A1 ARP010102329A ARP010102329A AR028579A1 AR 028579 A1 AR028579 A1 AR 028579A1 AR P010102329 A ARP010102329 A AR P010102329A AR P010102329 A ARP010102329 A AR P010102329A AR 028579 A1 AR028579 A1 AR 028579A1
Authority
AR
Argentina
Prior art keywords
acetilcoline
drought
nicotinic
vaginal
treatment
Prior art date
Application number
ARP010102329A
Other languages
English (en)
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AR028579A1 publication Critical patent/AR028579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP010102329A 2000-05-17 2001-05-16 Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica AR028579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/574,831 US6448276B1 (en) 2000-05-17 2000-05-17 Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
AR028579A1 true AR028579A1 (es) 2003-05-14

Family

ID=24297829

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102329A AR028579A1 (es) 2000-05-17 2001-05-16 Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica

Country Status (6)

Country Link
US (1) US6448276B1 (es)
EP (1) EP1253916A1 (es)
JP (1) JP2003533475A (es)
AR (1) AR028579A1 (es)
AU (1) AU2001261835A1 (es)
WO (1) WO2001087288A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20060035811A1 (en) * 2002-10-18 2006-02-16 Luis Molina Methods of treating dry eye disease with lantibiotics
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
FR2889188B1 (fr) * 2005-07-28 2007-09-07 Servier Lab Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent
WO2007055928A1 (en) * 2005-11-03 2007-05-18 Targacept, Inc. 5-membered ring metanicotine analogs
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
KR20110050680A (ko) * 2008-09-02 2011-05-16 뉴로서치 에이/에스 트리아졸 유도체, 및 니코틴성 아세틸콜린 수용체 조절제로서의 이들의 용도
US20110002966A1 (en) * 2009-07-01 2011-01-06 Alex Lovett Vaginal Suppository System and Method
CA2776971A1 (en) * 2009-10-05 2011-04-14 Vivus, Inc. Treatment with cholinergic agonists
US20130195780A1 (en) * 2010-09-17 2013-08-01 Rock Creek Pharmaceuticals, Inc. Skin Care Products Contianing Anatabine Or Derivative Thereof
JP6139408B2 (ja) * 2010-11-12 2017-05-31 ザ ユニバーシティ オブ ユタ リサーチ ファウンデーション 潤滑剤の制御送達のための膣内デバイス
WO2012149295A2 (en) * 2011-04-28 2012-11-01 Rock Creek Pharmaceuticals, Inc. Methods of administering anatabine to treat autism spectrum disorders and seizure disorders
KR20140124354A (ko) 2011-08-29 2014-10-24 알씨피 디벨롭먼트, 인크. 항염증 지원용 제품
WO2016161051A1 (en) * 2015-03-31 2016-10-06 Srq Patent Holdings, Llc Skin care products containing isomyosmine
WO2017142833A1 (en) * 2016-02-16 2017-08-24 Mymd Pharmaceuticals, Inc. Methods of increasing hair growth and improving hair appearance
US10709756B2 (en) 2016-10-26 2020-07-14 Olive Therapeutics, LLC Treating sexual dysfunction
WO2018093369A1 (en) * 2016-11-17 2018-05-24 Goren Ofer A Treatment of sexual dysfunction and for improved sexual quality of life
US20180193340A1 (en) * 2017-01-08 2018-07-12 Olive Therapeutics, LLC Treatment of sexual dysfunction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659078B1 (en) 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
CA2321991A1 (en) * 1998-02-24 1999-09-02 Wake Forest University Method for the treatment of pain, including chronic and female specific pain

Also Published As

Publication number Publication date
WO2001087288A8 (en) 2002-08-29
JP2003533475A (ja) 2003-11-11
US6448276B1 (en) 2002-09-10
EP1253916A1 (en) 2002-11-06
WO2001087288A2 (en) 2001-11-22
AU2001261835A1 (en) 2001-11-26

Similar Documents

Publication Publication Date Title
AR028579A1 (es) Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
AR028026A1 (es) Metodo para el tratamiento de la enfermedad del ojo seco con agonistas del receptor nicotinico de acetilcolina
LTPA2019521I1 (lt) Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
BR0117199B1 (pt) dispositivo para realização de osteosìntese.
DOP2005000024A (es) 2,3,4,5-tetrahidro-1h-benzo[d]azepinas 6-sustituidas como agonistas del receptor 5-ht2c
DK1110949T3 (da) EP4-receptorselektive agonister, som er anvendelige ved behandling af osteoporose
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
DK1789433T3 (da) Fremgangsmåder til at behandle kutan rødmen med selektive alfa-2-adrenerge receptoragonister
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DE502004002801D1 (de) Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren
BR0315138B1 (pt) aplicador de dispositivo para incontinÊncia vaginal.
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
NO20015259D0 (no) Substituerte bisykliske heterosykler, fremgangsmåte for deres fremstilling og deres anvendelse som antifedme oghyperkolesterolemiske midler
PT1355639E (pt) Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a
NO20032304D0 (no) Anvendelse av selektive dopamin D4-reseptoragonister for behandling av seksuell dysfunksjon
IL178887A0 (en) Novel beta agonists, method for producing the same and their use as drugs
AP2006003613A0 (en) Oral formulations for 5-HT-receptor agonists, usesand methods of treatment employing the same
PT1317430E (pt) Derivados de (2-azabiciclo[2.2.1]hepta-7-il)-metanol como agonistas do receptor nocotinico de acetilcolina
EP1565448A4 (en) PROCESS FOR THE PREPARATION OF 10H-DIBENZOçB, F] ç1,4] THIAZEPIN-11-ON
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
NO20054168D0 (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
DE60125360D1 (de) Abfrageprüfgerät, das Überabtastung zur Synchronisierung verwendet

Legal Events

Date Code Title Description
FB Suspension of granting procedure